Proportion of blasts with a clear halo around nucleoli at the end of induction therapy of acute myeloid leukemia correlates with achievement of complete remission, remission duration and relapse

Pathology International

Volumn 48, Issue 7, 1998, Pages 526-535

  Emura, Iwao ^a   Chou, Takaaki ^a   Ishiguro, Takurou ^a   Kakihara, Toshio ^a   Naito, Makoto ^a   Yoshizawa, Hirohisa ^a   Arakawa, Masaaki ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Acute myeloid leukemia; Clear halo around nucleolus; Papanicolaou stain; Prognosis; Residual leukemic cells

Indexed keywords

DAUNORUBICIN; ENOCITABINE; MERCAPTOPURINE; PREDNISOLONE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLAST TRANSFORMATION; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; DRUG EFFECT; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOLUS; OUTCOMES RESEARCH; PAPANICOLAOU TEST; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION;

EID: 0031826648     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1998.tb03944.x     Document Type: Article

References (45)

1. Ohno R, Tohru K, Mitune T et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. Cancer 1993; 71: 3888-3895.
2. Cassileth PA, Lynch E, Hines JD et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924-1930.
3. Mandelli F, Vegna ML, Avvisati G et al. A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: A report of the Italian cooperative group GIMEMA. Ann. Hematol. 1992; 64: 166-172.
4. Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 1994; 331: 896-903.
5. Vogler WR, Velez-Garcia E, Weiner RS et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A southeastern cancer study group study. J. Clin. Oncol. 1992; 10: 1103-1111.
6. Dillman RO, Davis RB, Green MR et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of cancer and leukemia Group B. Blood 1991; 78: 2520-2526.
7. Büchner TH, Urbanitz D, Hiddemann W et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J. Clin. Oncol. 1985; 3: 1583-1589.
8. Preisler H, Davis RB, Kirshner J et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: A cancer and leukemia group B study. Blood 1987; 69: 1441-1449.
9. The Toronto leukemia study group. Survival in acute myeloblastic leukemia is not prolonged by remission maintenance or early reinduction chemotherapy. Leuk. Res. 1988; 12: 195-200.
10. Zittoun R, Jehn U, Fière D et al. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: A randomized phase III study (AML6) of the EORTC leukemia cooperative group. Blood 1989; 73: 896-906.
11. Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ. Principal results of the medical research Council's 8th acute myeloid leukemia trial. Lancet 1986; 2: 1236-1241.
12. Sebban C, Archimbaud E, Coiffier B et al. Treatment of acute myeloid leukemia in elderly patients. A retrospective study. Cancer 1988; 61: 227-231.
13. Wasserman R, Galili N, Yoshinori I et al. Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J. Clin. Oncol. 1992; 10: 1879-1888.
14. Brisco MJ, Condon J, Hughes E et al. Outcome prediction in childhood acute lymphoblastic leukemia by molecular quantification of residual disease at the end of induction. Lancet 1994; 343: 196-200.
15. Sykes PJ, Neoh SH, Brisco MJ, Hughes E, Condon J, Morley AA. Quantitation of targets for PCR by use of limiting dilution. Biotechniques 1992; 13: 444-449.
16. Proctor DT. Preparatory techniques. In: Coleman DV, Chapman PA, ed. Clinical Cytotechnology. Butterworths, London, 1989; 52-78.
17. Emura I, Naito M, Kakihara T, Wakabayashi M, Hayashi N, Chou T. Identification of drug-resistant myeloid leukemic cells by measurement of DNA content, nuclear area, and detection of P-glycoprotein. Cancer 1996; 77: 878-887.
18. Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann. Intern. Med. 1985; 103: 620-625.
19. Kakihara T, Yamada T, Fukuda T, Ohnishi Y, Kishi K, Shibata A. Vincristine-resistant human leukemic cell line: New monoclonal antibodies to a 65 KDa membrane protein. Leuk. Lymphoma 1992; 7: 157-164.
20. Kenjirou H, Munehiro D, Hirokazu T et al. Heterogeneity of acute myeloid leukemia without maturation: An ultrastructural study. Ultrastruct. Pathol. 1995; 19: 9-14.
21. Lee EJ, Pollak A, Leavitt RD, Teatta JR, Schiffer CA. Minimally differentiated acute nonlymphocytic leukemia: A distinct entity. Blood 1987; 70: 1400-1406.
22. Mckenna RW, Parkin J, Bloomfield CD, Sundberg RD, Brunning RD. Acute promyelocytic leukemia: A study of 39 cases with identification of a hyperbasophilic microgranular variant. Br. J. Haematol. 1982; 50: 201-214.
23. Pearson EC. Ultrastructural feature in 100 cases of acute myeloid leukemia. Eur. J. Haematol. 1987; 38: 345-349.
24. Ochiai F, Eguchi M. Morphological evaluation of acute leukemic cells by electron microscopy. Virchows Arch. Cell Pathol. 1987; 52: 403-411.
25. Pearson EC, Wheatley K, Gray RG, Hayhoe FGT. The significance of ultrastructural features in acute myeloid leukemia: A study of 220 patients entered into medical research council's Minth acute myeloid leukemia trial. Leukemia 1989; 3: 548-553.
26. Begemann H, Rastetter J. Atlas der Klinischen Hämatologie. Springer-Verlag, Berlin, 1987.
27. Brunning RD, Mckenna RW. Atlas of Tumor Pathology. Tumor of the bone marrow. Fascicle 14, series 3. Armed Forces Institute of Pathology, Washington, DC, 1995.
28. Bessis M. Living Blood Cells and Their Ultrastructure. Springer-Verlag, Berlin, 1973.
29. Zucker-Franklin D, Greaves MF, Grossi CE et al. Atlas of Blood Cells. Function and Pathology, 2nd edn. Ediermes and Lea-Febiger, Philadelphia, 1988.
30. Tanaka Y, Goodman JR. Electron Microscopy of Human Blood Cells. Harper and Row, New York, 1972.
31. Polliack A. Human Leukemias: Cytochemical and Ultrastructural Techniques in Diagnosis and Research. Martinus Nijihoff, Boston, 1984.
32. Perry RP. Role of the nucleolus in ribonucleic acid metabolism and other cellular processes. National Cancer Institute Monograph. 1964; 14: 73-89.
33. Perry RP. On ribosome biogenesis. National Cancer Institute Monograph. 1966; 23: 527-545.
34. Frost JK. Pathologic processes affecting cells from inflammation to cancer. In: Bibbo M, ed. Comprehensive Cytopathology. WB Saunders Company, Philadelphia, 1991; 68-83.
35. Ghadially FN. Nucleus. In: Ghadially FN, ed. Ultrastructural Pathology of the Cell and Matrix, 4th edn. Butterworth-Heinemann, Boston, 1997; 1-184.
36. Koss LG. The basic structure of the mammalian cell. In: Koss LG, ed. Diagnostic Cytology, 4th edn. JB Lippincott Company, Philadelphia, 1992; 15-54.
37. Hoyes AD. The cell. In: Coleman DV, Chapman PA, eds. Clinical Cytotechnology. Butterworths, London, 1989; 7-28.
38. Ridge SN, Worwood M, Oscier D, Jacobs A, Padua RA. FMS mutation in myelodysplastic, leukemic and normal subjects. Proc. Natl Acad. Sci. USA 1990; 87: 1377-1380.
39. Farr CJ, Saiki RK, Erlich HA, McCormick F, Marshall CJ. Analysis of RAS gene mutation in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes. Proc. Natl Acad. Sci. USA 1988; 86: 1629-1633.
40. Fenaux P, Preudhomme C, Quiquandon I et al. Mutation of the P53 gene in acute myeloid leukemia. Br. J. Haemat. 1992; 80: 178-183.
41. Ahuja HG, Jat PS, Foti A, Bar-Eli M, Cline MJ. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 1991; 78: 3259-3268.
42. Kazushi I, Haruo S, Hiroyasu O et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071-3079.
43. Weinberg RA. Tumor suppressor genes. Science 1991; 254: 1138-1146.
44. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann. Intern. Med. 1966; 64: 328-342.
45. Pizzo PA, Meyers J. Infections in the cancer patient. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, 3rd edn. Lippincott, Philadelphia, 1989; 2088.